Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- USD | -.--% | -.--% | -.--% |
09/05 | Cullinan Therapeutics Insider Sold Shares Worth $1,796,676, According to a Recent SEC Filing | MT |
01/05 | Stifel Initiates Cullinan Oncology With Buy Rating, $40 Price Target | MT |
Sales 2015 | - | Sales 2016 | - | Capitalization | 5.08M 424M |
---|---|---|---|---|---|
Net income 2015 | - 0 | Net income 2016 | - 0 | EV / Sales 2015 | - |
Net Debt 2015 | 1.09M 90.8M | Net Debt 2016 | 330K 27.57M | EV / Sales 2016 | - |
P/E ratio 2015 |
-96.2
x | P/E ratio 2016 |
-17.6
x | Employees | - |
Yield 2015 * |
-
| Yield 2016 |
-
| Free-Float | 17.15% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 47 | - | |
Peter James Lee
DFI | Director of Finance/CFO | 66 | 01/08/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 47 | - |
1st Jan change | Capi. | |
---|---|---|
-.--% | 4M | |
+8.47% | 4.84B | |
+6.62% | 1.61B | |
+35.44% | 1.27B | |
+31.57% | 911M | |
+82.85% | 881M | |
+20.73% | 626M | |
-28.34% | 534M | |
-.--% | 155M | |
+18.97% | 125M |
- Stock Market
- Equities
- CGEM Stock